Dr. Winer Discusses Immunotherapy in Gynecologic Malignancies

Ira Winer, MD, PhD
Published: Tuesday, Apr 03, 2018



Ira Winer, MD, PhD, assistant professor, Division of Gynecologic Oncology, Barbara Ann Karmanos Cancer Institute at Wayne State Cancer Institute, discusses immunotherapy in gynecologic malignancies.

Immunotherapy has started to show promise in gynecologic malignancies. Winer says that it is being utilized in clinical trials of recurrent disease and in upfront trials. Currently, there is no way to select patients for these trials, Winer explains

Winer says that in a study of mutational burden, tumor immune checkpoint expression, and microsatellite instability in gynecologic malignancies, the implications for immune therapy were investigated.


Ira Winer, MD, PhD, assistant professor, Division of Gynecologic Oncology, Barbara Ann Karmanos Cancer Institute at Wayne State Cancer Institute, discusses immunotherapy in gynecologic malignancies.

Immunotherapy has started to show promise in gynecologic malignancies. Winer says that it is being utilized in clinical trials of recurrent disease and in upfront trials. Currently, there is no way to select patients for these trials, Winer explains

Winer says that in a study of mutational burden, tumor immune checkpoint expression, and microsatellite instability in gynecologic malignancies, the implications for immune therapy were investigated.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Community Practice Connections™: Redefining Ovarian Cancer Treatment Paradigms by Maximizing Therapeutic Outcomes with PARP InhibitorsSep 29, 20182.0
Publication Bottom Border
Border Publication
x